The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies
Open accessAbstract
Summary: Vascular disrupting agents (VDAs) are a relatively new group of ‘vascular targeting’ agents that exhibit selective activity against established tumour vascular networks, causing severe interruption of tumour blood flow and necrosis to the tumour mass. Microtubule depolymerizing agents form by far the largest group of small molecular weight VDAs many of which, including lead compound disodium combretastatin A‐4 3‐O‐phosphate (CA‐4‐P), are under clinical development for cancer. Although distinct from the angiogenesis inhibitors, VDAs can also interfere with angiogenesis and therefore constitute a potential group of novel drugs for the treatment of pathological conditions characterized by excessive angiogenesis, in addition to cancer. The endothelial cytoskeleton is the primary cellular target of this family of drugs, and some progress in understanding the molecular and signalling mechanisms associated with their endothelial disrupting activity has been made in the last few years. Susceptibility of tumour vessels to VDA damage is ascribed to their immature pericyte‐defective nature, although the exact molecular mechanisms involved have not been clearly defined. Despite causing profound damage to tumours, VDAs fail to halt tumour growth unless used together with conventional treatments. This failure is attributed to resistance mechanisms, primarily associated with cells that remain viable within the tumour rim, and enhanced angiogenesis. The focus is now to understand mechanisms of susceptibility and resistance to identify novel molecular targets and develop strategies that are more effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Conserved microtubule–actin interactions in cell movement and morphogenesis
Rodriguez, O. C., Schaefer, A. W., Mandato, C. A., Forscher, P., Bement, W. M., & Waterman-Storer, C. M. (2003) · Nature Cell Biology · doi:10.1038/ncb0703-599 · Cited by 844
Cited by
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
The chicken chorioallantoic membrane model in biology, medicine and bioengineering
Nowak-Sliwinska, P., Segura, T., & Iruela-Arispe, M. L. (2014) · Angiogenesis · doi:10.1007/s10456-014-9440-7 · Cited by 478
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives
Sun, R., Xiang, J., Zhou, Q., Piao, Y., Tang, J., Shao, S., Zhou, Z., Bae, Y. H., & Shen, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114614 · Cited by 433
Imidazoles as potential anticancer agents
Ali, I., Lone, M. N., & Aboul-Enein, H. Y. (2017) · Med. Chem. Commun. · doi:10.1039/c7md00067g · Cited by 409
The proliferation rate paradox in antimitotic chemotherapy
Mitchison, T. J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-04-0335 · Cited by 363
Metadata
- Authors
- Kanthou, C., & Tozer, G. M.
- Venue
- International Journal of Experimental Pathology
- Publisher
- Wiley
- Published
- 2009-05-11
- Volume
- 90
- Issue
- 3
- Pages
- 284-294
- ISSN
- 0959-9673 (ISSN-L)
- 1365-2613
- OpenAlex
- W1569973057
- Cited by
- 197
- References
- 3
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. https://app.cochat.ai/papers/10.1111/j.1365-2613.2009.00651.x
- The paper
- Kanthou, C., & Tozer, G. M. (2009). Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. International Journal of Experimental Pathology. https://doi.org/10.1111/j.1365-2613.2009.00651.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.